JOHNSON & JOHNSONJOHNSON & JOHNSONJOHNSON & JOHNSON

JOHNSON & JOHNSON

No trades
See on Supercharts

Key facts today

The European Medicines Agency has accepted the marketing application for AVT05, a biosimilar of Johnson & Johnson's Simponi and Simponi Aria. The approval process is expected to finish in Q4 2025.
Brett Kay from Johnson & Johnson discussed using real-world evidence and health data to support vulnerable groups at Empower 2024.
Analyze the impactAnalyze the impact
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪355.85 B‬EUR
‪12.84 B‬EUR
‪77.15 B‬EUR
‪2.40 B‬
Beta (1Y)
0.20
Employees (FY)
‪131.9 K‬
Change (1Y)
‪−20.8 K‬ −13.62%
Revenue / Employee (1Y)
‪645.58 K‬EUR
Net income / Employee (1Y)
‪101.03 K‬EUR

About Johnson & Johnson


CEO
Joaquin Duato
Headquarters
New Brunswick
Website
Founded
1887
FIGI
BBG01K3XQNH1
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬

See all ideas 

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
US478160CX0
JOHNSON&JOHN 24/54
Yield to maturity
5.11%
Maturity date
Jun 1, 2054
JNJJ
JOHNSON & JOHNSON 17/47
Yield to maturity
5.02%
Maturity date
Mar 3, 2047
US478160BV5
JOHNSON & JOHNSON 16/46
Yield to maturity
5.01%
Maturity date
Mar 1, 2046
US478160CM4
JOHNSON & JOHNSON 17/48
Yield to maturity
4.97%
Maturity date
Jan 15, 2048
US478160AN4
JOHNSON & JOHNSON 07/37
Yield to maturity
4.94%
Maturity date
Aug 15, 2037
US478160BA1
JOHNSON & JOHNSON 11/41
Yield to maturity
4.94%
Maturity date
May 15, 2041
US478160CL6
JOHNSON & JOHNSON 17/38
Yield to maturity
4.93%
Maturity date
Jan 15, 2038
JNJ.GR
Johnson & Johnson 5.85% 15-JUL-2038
Yield to maturity
4.90%
Maturity date
Jul 15, 2038
US478160CF9
JOHNSON & JOHNSON 17/37
Yield to maturity
4.88%
Maturity date
Mar 3, 2037
US478160CR3
JOHNSON&JOHN 20/40
Yield to maturity
4.84%
Maturity date
Sep 1, 2040
JNJ.GT
Johnson & Johnson 4.5% 01-SEP-2040
Yield to maturity
4.81%
Maturity date
Sep 1, 2040

Explore more bonds 

Frequently Asked Questions


The current price of 1JNJ is 145.94 EUR — it has decreased by −1.50% in the past 24 hours. Watch JOHNSON & JOHNSON stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on MIL exchange JOHNSON & JOHNSON stocks are traded under the ticker 1JNJ.
1JNJ stock has fallen by −2.04% compared to the previous week, the month change is a 0.37% rise, over the last year JOHNSON & JOHNSON has showed a 4.92% increase.
We've gathered analysts' opinions on JOHNSON & JOHNSON future price: according to them, 1JNJ price has a max estimate of 199.20 EUR and a min estimate of 144.54 EUR. Watch 1JNJ chart and read a more detailed JOHNSON & JOHNSON stock forecast: see what analysts think of JOHNSON & JOHNSON and suggest that you do with its stocks.
1JNJ reached its all-time high on Oct 22, 2024 with the price of 155.96 EUR, and its all-time low was 131.56 EUR and was reached on May 28, 2024. View more price dynamics on 1JNJ chart.
See other stocks reaching their highest and lowest prices.
1JNJ stock is 0.01% volatile and has beta coefficient of 0.20. Track JOHNSON & JOHNSON stock price on the chart and check out the list of the most volatile stocks — is JOHNSON & JOHNSON there?
Today JOHNSON & JOHNSON has the market capitalization of ‪354.51 B‬, it has decreased by −2.15% over the last week.
Yes, you can track JOHNSON & JOHNSON financials in yearly and quarterly reports right on TradingView.
JOHNSON & JOHNSON is going to release the next earnings report on Jan 28, 2025. Keep track of upcoming events with our Earnings Calendar.
1JNJ earnings for the last quarter are 2.17 EUR per share, whereas the estimation was 1.98 EUR resulting in a 9.68% surprise. The estimated earnings for the next quarter are 1.86 EUR per share. See more details about JOHNSON & JOHNSON earnings.
JOHNSON & JOHNSON revenue for the last quarter amounts to ‪20.18 B‬ EUR, despite the estimated figure of ‪19.91 B‬ EUR. In the next quarter, revenue is expected to reach ‪20.64 B‬ EUR.
1JNJ net income for the last quarter is ‪2.42 B‬ EUR, while the quarter before that showed ‪4.37 B‬ EUR of net income which accounts for −44.69% change. Track more JOHNSON & JOHNSON financial stats to get the full picture.
Yes, 1JNJ dividends are paid quarterly. The last dividend per share was 1.11 EUR. As of today, Dividend Yield (TTM)% is 3.04%. Tracking JOHNSON & JOHNSON dividends might help you take more informed decisions.
JOHNSON & JOHNSON dividend yield was 3.00% in 2023, and payout ratio reached 84.93%. The year before the numbers were 2.52% and 66.07% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Nov 5, 2024, the company has ‪131.90 K‬ employees. See our rating of the largest employees — is JOHNSON & JOHNSON on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. JOHNSON & JOHNSON EBITDA is ‪25.92 B‬ EUR, and current EBITDA margin is 34.82%. See more stats in JOHNSON & JOHNSON financial statements.
Like other stocks, 1JNJ shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade JOHNSON & JOHNSON stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So JOHNSON & JOHNSON technincal analysis shows the sell today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating JOHNSON & JOHNSON stock shows the neutral signal. See more of JOHNSON & JOHNSON technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.